Altimmune, Inc. (ALT)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). The investigation concerns whether Altimmune and certain of its officers and/or directors have violated federal securities laws.
On September 28, 2021, Altimmune reported 12-week data from the Phase 1 trial conducted in Australia for its product candidate pemvidutide in overweight and obese volunteers. While the Company touted the efficacy of the 1.8 mg arm of the study, its side effects stood out. For example, in the 1.8 mg arm, out of nine participants, about 56% had experienced mild nausea, the highest percentage in the multiple ascending doses (MAD) portion of the study. On this news, Altimmune’s stock price fell $3.88 per share, or 25.54%, over three trading sessions, to close at $11.31 per share on September 30, 2021.
If you are aware of any facts relating to this investigation, or purchased Altimmune shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.